诺诚健华：新型TYK2抑制剂Soficitinib III期注册临床研究完成患者入组

Core Viewpoint - The company announced significant progress in the clinical research of its novel TYK2 inhibitor soficitinib (ICP-332), with the completion of patient enrollment for the Phase III registration clinical trial, marking a crucial step in addressing AD disease [1] Group 1: Company Developments - The clinical trial for soficitinib has reached a major milestone with the completion of patient enrollment [1] - Soficitinib is a novel TYK2 inhibitor developed by the company [1] Group 2: Industry Context - TYK2 is a member of the Janus kinase (JAK) family and plays a critical role in the JAK-STAT signaling pathway, which is important in the mechanisms of inflammation [1]